IONIS PHARMACEUTICALS INC 4

EVP & Chief Development Officer Holly B. Kordasiewicz exercised 60,846 Ionis Pharmaceuticals stock options and sold 60,846 common shares (netting to 22,458 shares held) on June 12, 2026 under a Rule 10b5‑1 plan.

On June 12, 2026, Ionis Pharmaceuticals EVP and Chief Development Officer Holly B. Kordasiewicz exercised four tranches of non-qualified stock options for an aggregate 60,846 shares of common stock at strike prices of $32.60, $56.78, and $60.89, acquiring shares at an implied value of roughly $3.6–$4.4 million based on the contemporaneous market prices. On the same day, pursuant to a pre‑arranged Rule 10b5‑1 trading plan, she sold a total of 60,846 shares in two open-market transactions: 41,004 shares at a weighted average price of $73.0934 and 19,842 shares at a weighted average price of $74.0503, generating gross sale proceeds of approximately $4.5 million. These paired option exercises and sales appear to represent a largely cashless or monetizing transaction rather than a directional change in exposure, and after all transactions she held 22,458 shares of Ionis common stock directly. The option awards exercised had original grant dates in 2021–2023 and long-dated expirations, indicating that the exercises were of previously granted compensation awards rather than new grants.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

sec

Accession

0000874015-26-000208

Alert Tier

6